Elsiglutide
From PeptidePlaza, the free peptide reference · Entry #1194 · Metabolic · Sources fetched 2026-09-11 · Editorial standards
Elsiglutide is a metabolic research peptide. Elsiglutide is a glucagon-like peptide 2 receptor agonist currently in Phase 2 clinical trials for the treatment of diarrhea.
Elsiglutide is a synthetic peptide that acts as an agonist for the glucagon-like peptide 2 (GLP-2) receptor. Its mechanism of action involves stimulating GLP-2 receptors, which are involved in intestinal growth and function. Research has explored its potential in reducing diarrhea, particularly that caused by certain chemotherapy agents. It is currently undergoing Phase 2 clinical development.
1 Mechanism of action
Glucagon-like peptide 2 receptor agonist (agonist)
Primary targets: Glucagon-like peptide 2 receptor
2 Reported effects
Effects below are those reported in the published literature cited on this page. They are not claims of clinical benefit and not medical advice.
2.1 Indicated / studied for
- Diarrhea
3 Chemical and physical properties
| Purity (typical) | Not independently verified |
|---|---|
| Storage | −20 °C, lyophilised powder, desiccated |
| Solubility | Sterile water / bacteriostatic water |
| Receptors / targets | Glucagon-like peptide 2 receptor |
4 Research studies (1)
- The GLP-2 analogue elsiglutide reduces diarrhoea caused by the tyrosine kinase inhibitor lapatinib in rats
Cancer chemotherapy and pharmacology (2020)
5 Safety and risk profile
5.1 Regulatory status
Elsiglutide is currently classified as Phase 2 clinical trials. It has no approved human indication in the United States; availability elsewhere does not imply demonstrated safety or efficacy.
6 Frequently asked questions
- What is Elsiglutide?
- Elsiglutide is a synthetic peptide that functions as a glucagon-like peptide 2 (GLP-2) receptor agonist. It is being investigated for its therapeutic potential in conditions involving intestinal function.
- How does Elsiglutide work?
- Elsiglutide works by activating the glucagon-like peptide 2 (GLP-2) receptor. This activation is associated with effects on intestinal growth and nutrient absorption, which may help in conditions like diarrhea.
- What is Elsiglutide used for?
- Elsiglutide is being studied for its use in treating diarrhea. Early research has specifically looked into its ability to reduce diarrhea caused by certain cancer treatments.
- What is the regulatory status of Elsiglutide?
- Elsiglutide is currently in Phase 2 clinical trials. This means it is undergoing further testing in a larger group of people to evaluate its effectiveness and safety for its intended use.
7 References
- Elsiglutide — molecule record ChEMBL. View source
- Elsiglutide — published literature (1 records) PubMed. View source
Related compounds
Entries that share a target, a mechanism, or a research area with Elsiglutide.
Also metabolic
Dulaglutide, marketed as TRULICITY, is a glucagon-like peptide-1 (GLP-1) receptor agonist used to improve glycemic control and reduce cardiovascular risk in adults with type 2 diabetes mellitus.
Also metabolic
Lixisenatide, also known as Adlyxin, is a glucagon-like peptide-1 (GLP-1) receptor agonist used to improve glycemic control in adults with type 2 diabetes mellitus.
Also metabolic
Albiglutide is a glucagon-like peptide 1 (GLP-1) receptor agonist used in the treatment of type 2 diabetes mellitus.
Also metabolic
Taspoglutide is a glucagon-like peptide 1 receptor agonist that was investigated for the treatment of Type 2 Diabetes Mellitus.